Innovative Product Portfolio Cortechs.ai has developed the FDA-cleared NeuroQuant® and NeuroQuant Brain Tumor software, which offer fully automated quantitative MRI analysis for neurological disorders and brain tumors. These advanced tools provide significant value for clinics and research centers focused on neurodegenerative diseases and oncology, presenting strong opportunities to expand sales within hospitals and specialty clinics.

Strategic Partnerships & Collaborations Recent collaborations with industry leaders like Philips and partnerships with Alzheimer's research networks such as ALZ-NET highlight Cortechs.ai’s active engagement with major health technology players and research institutions. These alliances facilitate market penetration and create avenues for deploying cutting-edge imaging solutions in broader clinical and research settings.

Expansion Through Acquisitions The company's acquisition of ZepMed’s CT imaging technology and neuroimaging assets demonstrates a growth strategy that enhances its product suite and broadens its diagnostic capabilities. This positions Cortechs.ai for cross-selling opportunities across diverse imaging modalities and regulatory approvals, appealing to clinics seeking integrated neurodiagnostic solutions.

Market Leadership & Recognition As a pioneer in AI-powered neuroimaging with FDA and CE certifications, Cortechs.ai is well-positioned as a trusted provider for neurologists, radiologists, and oncologists. Its reputation as a leader in technological innovation can be leveraged to attract new enterprise customers and accelerate adoption in high-end medical centers.

Growing Revenue & Market Presence With revenues estimated between 10 and 25 million dollars and active expansion efforts, Cortechs.ai is demonstrating market traction and potential for further growth. This financial stability and increasing industry recognition open opportunities to target larger healthcare systems, research institutions, and specialty clinics looking for advanced neuroimaging solutions.